

Supporting Information

A dimethoxytriazine type glycosyl donor enables facile chemo-enzymatic route toward α -linked *N*-acetylglucosaminyl-galactose disaccharide unit from gastric mucin

Masato Noguchi^a, Miwa Nakamura^a, Ayaka Ohno^a, Tomonari Tanaka^b, Atsushi Kobayashi^a, Masaki Ishihara^a, Masaya Fujita^b, AKiko Tsuchida^c, Mamoru Mizuno^c and Shin-ichiro Shoda*^a

^aGraduate School of Engineering, Tohoku University, 6-6-11-514 Aoba, Sendai 980-8579, Japan.
Fax: +81-22-795-7293; Tel: +81-22-795-7230; E-mail:shoda@poly.che.tohoku.ac.jp

^bDepartment of Biobased Materials Science, Kyoto Institute of Technology, Matsugasaki, Sakyo-ku, Kyoto 606-8585, Japan

^cThe Noguchi Institute, 1-8-1 Kaga, Itabashi, Tokyo 173-0003, Japan

Supplementary Material

Table of Contents

Synthesis of 1	2
Hydrolysis of 1 by α - <i>N</i> -acetylglucosaminidase	2
Transglycosylation catalyzed by α - <i>N</i> -acetylglucosaminidase	2
¹ H NMR and ¹³ C NMR spectra of 1	6
¹ H NMR and ¹³ C NMR spectra of 6a	8
¹ H NMR and ¹³ C NMR spectra of 6b	10
¹ H NMR and ¹³ C NMR spectra of 6c	12
¹ H NMR and ¹³ C NMR spectra of 6d	14
¹ H NMR and ¹³ C NMR spectra of 6e	16

Synthesis of **1**

4-(4,6-dimethoxy-1,3,5-triazine-2-yl)-4-methyl morpholinium chloride (DMT-MM, 533 mg, 2.0 mmol) was added to a solution of *N*-acetylglucosamine (221 mg, 1.0 mmol) and lutidine (0.23 ml, 2.0 mmol) in water (6.25 ml), and the resulting mixture was stirred for 24 h at room temperature. After concentration in vacuo, the residue was purified by silica gel column chromatography (eluent : ethyl acetate / methanol = 7/1) to give 4,6-dimethoxy-1,3,5-triazin-2-yl α -*N*-acetylglucosaminide (288 mg, 0.84 mmol, 84%).

^1H NMR(500 MHz, D_2O) : δ 6.38(1H, d, H-1, $J_{1,2} = 3.3$ Hz), 4.03(1H, dd, H-2, $J_{1,2} = 3.3$ Hz, $J_{2,3} = 10.8$ Hz), 3.89(6H, s, $-\text{OCH}_3$), 3.83(1H, dd, H-3, $J_{2,3} = 10.6$ Hz, $J_{3,4} = 9.9$ Hz), 3.74-3.66(3H, m, H-5, H-6a, H-6b), 3.51(1H, t, H-4, $J_{3,4} = J_{4,5} = 9.4$ Hz), 1.85(3H, s, $-\text{COCH}_3$)

^{13}C NMR(126 MHz, D_2O) : δ 174.7, 173.2, and 171.7(triazine, $-\text{COCH}_3$), 94.3(C-1), 74.2(C-5), 70.4(C-3), 69.3(C-4), 60.1(C-6), 55.8($-\text{OCH}_3$), 52.8(C-2), 21.6($-\text{COCH}_3$).

ESI-MS : m/z calcd for $\text{C}_{13}\text{H}_{20}\text{N}_4\text{O}_8[\text{M}+\text{Na}]^+$: 383.1173, Found : 383.1174.

Enzymatic hydrolysis of **1** by α -*N*-acetylglucosaminidase

A mixture of **1** (5 μmol , final conc.: 10 mM) and α -*N*-acetylglucosaminidase B1 (5.0 μg , 5 μl) in PBS (pH 7.4) was incubated at 37 $^\circ\text{C}$. The reaction mixtures were analysed by HPLC (column; TOSOH TSK-Gel Amide-80 ($\phi 4.6 \times 250$ mm), eluent; 75 vol.% CH_3CN , flow rate; 1.0 ml/min, column oven; 30 $^\circ\text{C}$, detection; UV (214 nm)).

Synthesis of **6a**

A mixture of **1** (50 μmol , final conc.: 50 mM), *p*-methoxyphenyl β -galactoside (50 μmol , final conc.: 50 mM), and α -*N*-acetylglucosaminidase B1 (100 μg , 36.4 μl , PBS solution) in 100 mM sodium phosphate buffer (pH 6.5) was incubated at 37 $^\circ\text{C}$. The reaction mixtures were analyzed by HPLC (column; Inertsil ODS-3 ($\phi 4.6 \times 250$ mm, GL-Sciences), eluted by 5% CH_3CN to 15% CH_3CN gradient, flow rate; 1.0 ml/min, column oven; 30 $^\circ\text{C}$, detection; UV (280 nm)). The products were purified by HPLC (column; COSMOSIL Cholester (20 \times 250 mm, nacalai tesque), eluent; 8 vol.% CH_3CN , flow rate; 18.9 ml/min, column oven; 30 $^\circ\text{C}$, detection; UV (280 nm)), concentrated *in vacuo*, and freeze-dried.

^1H NMR (500 MHz, CD_3OD): δ 7.08 (2H, d, Ph, $J = 9.1$ Hz), 6.86 (2H, d, Ph, $J = 9.1$ Hz), 4.95 (1H, d, H-1', $J = 3.6$ Hz), 4.84 (1H, d, H-1, $J = 7.6$ Hz), 4.29 (1H, ddd, H-5', $J = 2.5, 4.0, 9.9$ Hz), 4.04 (1H, d, H-4, $J = 2.8$ Hz), 3.97 (1H, dd, H-2', $J = 3.6, 10.9$ Hz), 3.83 (1H, dd, H-6a', $J = 2.2, 11.8$ Hz), 3.79-3.71 (8H, m, H-2, H-5, H-6a, H-3', H-6'b, OCH_3), 3.69-3.65 (2H, m, H-3, H-6b), 3.46 (1H, t, H-4', $J = 9.4, 9.5$ Hz), 2.02 (3H, s, CH_3).

^{13}C NMR (126 MHz, CD_3OD): δ 173.8 (CO of Ac), 156.7 (Ph), 153.0 (Ph), 119.1 (Ph), 115.5 (Ph), 104.0 (C-1), 100.3 (C-1'), 77.7 (C-4), 76.8 (C-5), 74.3 (C-3), 73.7 (C-5'), 72.6 (C-3'), 72.4 (C-2),

72.0 (C-4'), 62.3 (C-6'), 60.7 (C-6), 56.1 (OCH₃), 55.5 (C-2'), 22.7 (CH₃ of Ac).

Synthesis of **6b**

A mixture of **1** (45 mg, 0.125 mmol, final conc.: 50 mM), methyl β-galactoside (73 mg, 0.375 mmol, final conc.: 150 mM), and α-*N*-acetylglucosaminidase B1 (385 μg, 134 μl, PBS solution) in 100 mM sodium phosphate buffer (pH 6.5 final volume 2.5 ml) was incubated at 37 °C for 1 hour. The product was purified by HPLC (column; Amide-80 (21.5 mm I.D. × 250 mm, Tosoh), eluent; 80 vol.% CH₃CN, flow rate; 8 ml/min, column oven; 30 °C, detection; UV (214 nm)), concentrated *in vacuo*, and freeze-dried to give methyl 4-*O*-(2-acetamido-2-deoxy-α-glucopyranosyl)-β-galactopyranoside (**6b**, 7.8 mg, 17%).

¹H NMR (500 MHz, CD₃OD) : δ 4.88(1H, d, H-1', *J* = 3.7 Hz), 4.24(1H, ddd, H-5', *J* = 2.5, 4.4, 10.2 Hz), 4.21(1H, d, H-1, *J* = 7.4 Hz), 3.97(H1, d, H-4, *J* = 3.0 Hz), 3.94(H1, dd, H-2', *J* = 3.7, 10.8 Hz), 3.79(1H, dd, H-6'a, *J* = 2.6, 11.8 Hz), 3.74-3.63(5H, m, H-6'b, H-6, H-3', H-6, H-5), 3.58(3H, s, -OCH₃), 3.55(1H, dd, H-3, *J* = 3.0, 10.1 Hz), 3.50(1H, dd, H-2, *J* = 7.5, 10.1 Hz), 3.43(1H, dd, H-4', *J* = 9.0, 10.1 Hz), 2.03(3H, s, -COCH₃).

¹³C NMR (126 MHz, CD₃OD) : δ 173.7(-COCH₃), 106.3(C-1), 100.3(C-1'), 77.6(C-4), 76.7(C-5), 74.4(C-3), 73.6(C-5'), 72.7(C-3'), 72.6(C-2), 72.0(C-4'), 62.3(C-6'), 60.8(C-6), 57.8(-OCH₃), 55.5(C-2'), 22.7(-COCH₃)

Synthesis of **6c**

A mixture of **1** (40 mg, 0.11 mmol, final conc.: 50 mM), *i*-propyl 1-thio β-galactoside (79 mg, 0.33 mmol, final conc.: 150 mM), and α-*N*-acetylglucosaminidase B1 (340 μg, 118 μl, PBS solution) in 100 mM sodium phosphate buffer (pH 6.5, final volume 2.2 ml) was incubated at 37 °C for 1 hour. The product was purified by HPLC (column; Amide-80 (21.5 mm I.D. × 250 mm, Tosoh), eluent; 80 vol.% CH₃CN, flow rate; 8 ml/min, column oven; 30 °C, detection; UV (214 nm)), concentrated *in vacuo*, and freeze-dried to give *i*-propyl 1-thio 4-*O*-(2-acetamido-2-deoxy-α-glucopyranosyl)-β-galactopyranoside (**6c**, 14 mg, 29%).

¹H NMR (500 MHz, CD₃OD) : δ 4.89(1H, d, H-1', *J* = 3.7 Hz), 4.51(1H, d, H-1, *J* = 9.6 Hz), 4.22(1H, ddd, H-5', *J* = 2.5, 4.4, 10.1 Hz), 4.01(1H, d, H-4, *J* = 3.0 Hz), 3.95(1H, dd, H-2', *J* = 3.7, 10.8 Hz), 3.79(1H, dd, H-6'a, *J* = 2.5, 11.8 Hz), 3.73(1H, dd, H-6'b, *J* = 4.5, 11.8 Hz), 3.70-3.59(4H, m, H-3', H-5, H-6a, H-6b), 3.56(1H, dd, H-3, *J* = 3.0, 9.6 Hz), 3.48(1H, t, H-2, *J* = 9.6 Hz), 3.43(1H, dd, H-4', *J* = 9.0, 10.1 Hz), 3.25(1H, m, isopropyl, *J* = 6.8 Hz), , 2.03(3H, s, -COCH₃). 1.34(3H, d, isopropyl, *J* = 4.2 Hz), 1.33(3H, d, isopropyl, *J* = 4.4 Hz).

¹³C NMR (126 MHz, CD₃OD) : δ 173.7(-COCH₃), 100.53(C-1'), 87.3(C-1), 80.5(C-5), 78.3(C-4), 75.9(C-3), 73.6(C-5'), 72.7(C-3'), 72.0(C-4'), 71.7(C-2), 62.3(C-6'), 60.8(C-6), 55.5(C-2'), 24.4, 24.1(isopropyl), 22.7(-COCH₃).

Synthesis of **6d**

A mixture of **1** (32.4 mg, 90 μ mol, final conc.: 75 mM), 2-pyridyl 1-thio-2-acetamido-2-deoxy-4-*O*- β -galactopyranosyl- β -glucopyranoside (14.3 mg, 30 μ mol, final conc.: 25 mM), and α -*N*-acetylglucosaminidase B1 (120 μ g, 43 μ l, PBS solution) in 100 mM sodium phosphate buffer (pH 6.5, final volume 1.2 ml) was incubated at 37 °C for 3 hours. The product was purified by HPLC (column; Amide-80 (21.5 mm I.D. \times 250 mm, Tosoh), eluent; 75 vol.% CH₃CN, flow rate; 8 ml/min, column oven; 30 °C, detection; UV (240 nm)), concentrated *in vacuo*, and freeze-dried to give 2-pyridyl 1-thio-2-acetamido-2-deoxy-4-*O*-(4-*O*-(2-acetamido-2-deoxy- α -glucopyranosyl)- β -galactopyranosyl)- β -glucopyranoside (**6d**, 8.2 mg, 39%).

¹H NMR (400 MHz, CD₃OD): δ 8.38, 7.68, 7.40, and 7.16(4H, Pyridyl), 5.45(1H, d, H-1, J = 10.7 Hz), 4.90(1H, d, H-1'', J = 3.7 Hz), 4.48(1H, d, H-1', J = 7.4 Hz), 4.20(1H, ddd, H-5'', J = 2.4, 4.6, 7.8 Hz), 3.99(1H, dd, H-2, J = 9.6, 10.5 Hz), 3.95(1H, d, H-4', J = 2.2 Hz), 3.93-3.89(3H, m, H-6a, H-6b, H-2''), 3.81(1H, dd, H-6''a, J = 2.5, 11.9 Hz), 3.78-3.54(10H, m, H-3, H-4, H-5, H-2', H-3', H-5', H-6'a, H-6'b, H-3'', H-6''b), 3.42(1H, dd, H-4'', J = 8.9, 10.1 Hz), 2.01(3H, s, -COCH₃), 1.95(3H, s, -COCH₃).

¹³C NMR (100 MHz, CD₃OD): δ 173.7 and 173.5(-COCH₃), 158.9, 150.3, 138.5, 124.4, and 122.0(Pyridyl), 105.4(C-1'), 100.1(C-1''), 84.8(C-1), 80.9(C-5), 80.6(C-4), 78.1(C-4'), 77.2(C-5'), 75.7(C-3), 74.5(C-3'), 73.8(C-5''), 72.5(C-2', C-3''), 72.1(C-4''), 62.4(C-6''), 61.8(C-6), 61.3(C-6'), 55.6(C-2''), 55.5(C-2), 22.9 and 22.7(-COCH₃).


Synthesis of **6e**

A mixture of **1** (28.8 mg, 80 μ mol, final conc.: 50 mM), 4,6-dimethoxy-1,3,5-triazine-2-yl 2-acetamido-2-deoxy-3-*O*- β -galactopyranosyl- α -D-galactopyranoside (20.9 mg, 40 μ mol, final conc.: 25 mM), and α -*N*-acetylglucosaminidase B1 (240 μ g, 88 μ l, PBS solution) in 100 mM sodium phosphate buffer (pH 6.5, final volume 1.6 ml) was incubated at 37 °C for 4 hours. The product was purified by HPLC (column; Amide-80 (21.5 mm I.D. \times 250 mm, Tosoh), eluent; 75 vol.% CH₃CN, flow rate; 8 ml/min, column oven; 30 °C, detection; UV (214 nm)), concentrated *in vacuo*, and freeze-dried to give 4,6-dimethoxy-1,3,5-triazine-2-yl 2-acetamido-2-deoxy-3-*O*-(4-*O*-(2-acetamido-2-deoxy- α -glucopyranosyl)- β -galactopyranosyl)- α -galactopyranoside (**6e**, 12.7 mg, 44%).

¹H NMR (400 MHz, CD₃OD): δ 6.63(1H, d, H-1, J = 3.72 Hz), 4.93(1H, d, H-1'', J = 3.7 Hz), 4.66(1H, dd, H-2, J = 3.7, 11.3 Hz), 4.56(1H, d, H-1', J = 7.1 Hz), 4.27(1H, d, H-4, J = 2.1 Hz), 4.20-4.16(2H, m, H-3, H-5''), 4.02-4.00(7H, m, -OCH₃, H-5), 3.97(1H, d, H-4', J = 2.8 Hz), 3.94(1H, dd, H-2'', J = 3.7, 10.9 Hz), 3.81(1H, d, H-6''a, J = 2.3 11.8 Hz), 3.76-3.54(9H, m, H-6a, H-6b, H-2',


H-3', H-5', H-6'a, H-6'b, H-3'', H-6''b), 3.42(1H, dd, H-4'', $J = 8.9, 10.0$ Hz), 2.02(3H, s, -COCH₃), 1.92(3H, s, -COCH₃).


¹³C NMR (101 MHz, CD₃OD): δ 175.1, 174.3, 173.8, and 173.7(triazine, -COCH₃), 106.1(C-1'), 100.1(C-1''), 96.4(C-1), 78.4(C-3), 78.1(C-4'), 76.8(C-5'), 74.8(C-5), 74.5(C-3'), 73.8(C-5''), 72.6(C-3''), 72.5(C-2'), 72.1(C-4''), 69.5(C-4), 62.5(C-6), 62.4(C-6''), 61.3(C-6'), 56.1(-OCH₃), 55.6(C-2''), 49.6-48.4(C-2 in peak of CD₃OD), 22.7 and 22.6(-COCH₃).




¹³C NMR spectrum of **1**

^1H NMR spectrum of **6a**







^{13}C NMR spectrum of **6a**




¹H NMR spectrum of **6b**




^{13}C NMR spectrum of **6b**




¹H NMR spectrum of **6c**



^{13}C NMR spectrum of **6c**





^1H NMR spectrum of **6d**



^{13}C NMR spectrum of **6d**

^1H NMR spectrum of **6e**





^{13}C NMR spectrum of **6e**